New Therapies in Veterinary Oncology.

Authors :: Mullin C
Clifford CA
Johannes CM
Source :: The Veterinary clinics of North America. Small animal practice [Vet Clin North Am Small Anim Pract] 2024 May; Vol. 54 (3), pp. 469-476. Date of Electronic Publication: 2024 Jan 06.
Publication Year :: 2024
Abstract: The expanding number of specialized oncology therapeutics available in veterinary oncology can make staying updated on the most recent advances challenging. This article summarizes the mechanism of action, available supporting data, and clinical use of three key veterinary cancer/supportive care therapeutics: Laverdia-CA1, Canalevia-CA1, and Stelfonta. This information will help guide clinical use within your practice and can be incorporated into discussions with clients regarding the newest available options for their dogs with cancer.<br />Competing Interests: Disclosure C. Mullin: No disclosures to report. C.A. Clifford: Speaker, advisory board member and consultant with Jaguar Animal Health and Anivive. C.M. Johannes: Speaker, advisory board member and consultant with QBiotics Group; advisory board member with Jaguar Animal Health.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)